By effectively blocking F-actin cross-linking activity of FSCN1[40], NP-G2-044 has demonstrated anti-tumor metastasis effects in preclinical studies[28, 42–46] and in a phase Ia clinical trial for patients with metastatic or advanced refractory solid tumor malignancies (Clinicaltrials.gov NCT03199586). The gene discussed is FSCN1; the disease is neoplasm.